Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors

Published:2020-08-11 Issue:10 Volume:11 Page:2793-2803
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Choi Yong Jun¹^ORCID,Kim Taehee¹^ORCID,Kim Eun Young¹,Lee Sang Hoon¹,Kwon Do Sun¹,Chang Yoon Soo¹

Affiliation:

1. Department of Internal Medicine Yonsei University College of Medicine Seoul South Korea

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13594

Reference37 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cancer statistics, 2000

3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer;Frontiers in Immunology;2024-08-22

2. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;Clinical Lung Cancer;2024-06

3. Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;2024-01-05

4. Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study;Cancer Cell International;2023-09-30

5. Accumulation of plasmacytoid dendritic cell is associated with a treatment response to DNA-damaging treatment and favorable prognosis in lung adenocarcinoma;Frontiers in Immunology;2023-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3